All In MedTech

Device Trial Radar · NCT07228117

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 389 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

389

Actual

Start

Feb 2, 2026

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Medtronic MiniMed, Inc.Public (MDT)
Sponsor type
Industry
First posted
Nov 14, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 7 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to check that a new insulin pump, called NMX8, is safe when used with a continuous glucose monitoring sensor called Disposable Sensor 5/Simplera Sync in people with diabetes. The study will include people with Type 1 diabetes who are 7-85 years old and people with Type 2 diabetes who are 18-85 years old. Participants will use their current therapy while also wearing the DS5/Simplera sensor for up to 40 days. During this time, they will complete a meal and exercise log. Participants will then be placed into one of three groups by chance and given the NMX8 pump to use for about 90 days. During this time, participants will bolus, not bolus, or bolus at will for meals and continue to complete a meal and exercise log depending on the group they are in. Once their part in the study is over, if participants like the pump and want to keep using it, they may be able to join a Continued Access Period to keep using the NMX8 pump.

Conditions

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus

Interventions

  • MiniMed™ NMX8-AID System with DS5™/Simplera Sync™Device

    Patients will be provided with the NMX8 system with DS5/Simplera Sync CGM.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study Arm 1: Percent of Time in Range (TIR 70-180 mg/dL)Time frame: Throughout the study period, approximately 90 days.
  2. Study Arm 1: Percent of Time in Hypoglycemia (< 70 mg/dL)Time frame: Throughout the study period, approximately 90 days.
  3. Study Arm 2: Percent of Time in Range (TIR 70-180 mg/dL)Time frame: Throughout the study period, approximately 90 days.

3 more outcomes with a free account

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Medical Investigations

    Little Rock, Arkansas

  • Headlands Research California, LLC

    Escondido, California

  • Sansum Diabetes Research Institute

    Goleta, California

30 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.